Company Filing History:
Years Active: 2014
Title: Michael Goldbiatt: Innovator in Viral Infection Treatment
Introduction
Michael Goldbiatt is a notable inventor based in McLean, VA (US). He has made significant contributions to the field of medicine, particularly in the treatment of viral infections. His innovative work has the potential to impact the lives of many individuals affected by serious viral diseases.
Latest Patents
Goldbiatt holds a patent for "Anti-TSG101 antibodies and their uses for treatment of viral infections." This invention provides antibodies that bind to the C-terminal region of TSG101. The methods outlined in this patent focus on using TSG101 antibodies for the treatment of viral infections, including HIV and Ebola virus infection. This patent represents a significant advancement in therapeutic options for these serious conditions. He has 1 patent to his name.
Career Highlights
Michael Goldbiatt is currently associated with Eli Lilly and Company, a leading global pharmaceutical company. His work at Eli Lilly has allowed him to collaborate with other talented professionals in the field. His contributions to the company and the medical community are noteworthy.
Collaborations
Goldbiatt has worked alongside esteemed colleagues such as Limin Li and Michael Scott Kinch. These collaborations have fostered an environment of innovation and have led to advancements in the treatment of viral infections.
Conclusion
Michael Goldbiatt's work in developing anti-TSG101 antibodies showcases his commitment to advancing medical science. His contributions have the potential to change the landscape of treatment for viral infections.